证券代码：600518 证券简称：ST康美 编号：临2023-034 康美药业股份有限公司关于康美实业 所持公司部分股份将被司法拍卖的提示性公告（三） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次将被司法拍卖的股份为康美实业投资控股有限公司（以下简称康美 实业）持有的公司无限售流通股 155,290,000 股，占公司总股本的 1.12%。 截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股本 的 5.21%。若本次司法拍卖成功，不会导致公司控股股东及实际控制人发生变化， 亦不会对公司经营活动产生影响。 目前上述司法拍卖事项尚在公示阶段，后续将涉及竞拍、缴款、股权变 更过户等环节，拍卖结果尚存在不确定性，公司将根据后续进展及时履行信息披 露义务。 康美药业股份有限公司（以下简称公司）股东康美实业所持有的公司股票将 依法被康美实业管理人分批公开处置。公司于今日获知，康美实业管理人将对第 一批司法拍卖的康美实业持有的公司无限售流通股 155,290,000 股进行第二次 公开处置，现 ...

证券代码：600518 证券简称：ST康美 编号：临2023-033 一、康美实业持有公司股份被拍卖的基本情况 康美药业股份有限公司关于康美实业 所持公司部分股份将被司法拍卖的提示性公告（二） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次将被司法拍卖的股份为康美实业投资控股有限公司（以下简称康美 实业）持有的公司无限售流通股 7,666,895 股，占公司总股本的 0.06%。 截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股本 的 5.21%。若本次司法拍卖成功，不会导致公司控股股东及实际控制人发生变化， 亦不会对公司经营活动产生影响。 目前上述司法拍卖事项尚在公示阶段，后续将涉及竞拍、缴款、股权变 更过户等环节，拍卖结果尚存在不确定性，公司将根据后续进展及时履行信息披 露义务。 康美药业股份有限公司（以下简称公司）股东康美实业所持有的公司股票将 依法被康美实业管理人分批公开处置。公司于今日获知，康美实业管理人第二批 司法拍卖股票标的为康美实业持有的公司无限售流通股 7,66 ...

证券代码：600518 证券简称：ST康美 编号：临2023-032 康美药业股份有限公司关于康美实业 所持公司部分股份被司法拍卖的进展公告 二、其他相关说明及风险提示 （一）截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股 本的 5.21%，本次被拍卖的公司股份后续是否二次被拍卖具有不确定性。若拍卖 最终举行，涉及的竞拍、缴款、法院执行法定程序、股权变更过户等环节均存在 一定的不确定性。公司将根据法院执行情况，及时履行相应的信息披露义务。 （二）康美实业持有公司股份被拍卖事项，不会导致公司控股股东及实际控 制人发生变化，亦不会对公司经营活动产生影响。 （三）康美实业已被裁定宣告破产，其持有的公司股份后续将被分批进行公 开处置。公司将及时履行信息披露义务，敬请广大投资者理性投资并注意投资风 险。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）于 2023 年 8 月 16 日披露了《康美 药业关于康美实业所持公司部分股份将被司法拍卖的提示性公告》（公告编号： ...

证券代码：600518 证券简称：ST康美 编号：临2023-031 康美药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日（星期四）下午 13:00-14:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 09 月 07 日（星期四）至 09 月 13 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进行提问。公司将在业绩说明会上对投资者普遍关注 的问题进行回答。 康美药业股份有限公司（以下简称公司）已于 2023 年 08 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经 营成果、财务状况，公司计划于 202 ...

康美药业股份有限公司关于全资子公司 收到法院不予受理破产清算裁定的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司全资子公司康美中药城（普宁）有限公司收到揭阳中院送达的《民 事上诉状》，深圳中科恒实业有限公司不服揭阳中院做出的裁定，向广东省高 级人民法院提起上诉。 2023 年 8 月 28 日，康美药业股份有限公司（以下简称公司）全资子公司 康美中药城（普宁）有限公司（以下简称普宁中药城或被上诉人）收到广东省 揭阳市中级人民法院（以下简称揭阳中院）送达的《民事上诉状》，深圳中科 恒实业有限公司（以下简称中科恒或上诉人）不服揭阳中院做出的（2023）粤 52 破申 5 号民事裁定书，向广东省高级人民法院（以下简称广东高院）提起上 诉，现将相关情况公告如下： 一、普宁中药城被申请破产清算的基本情况 证券代码：600518 证券简称：ST康美 编号：临2023-030 二、本次事项对公司的影响 若普宁中药城进入破产清算程序，对公司中药城业务收入影响较小，公司 中药城资产规模相应缩小。 截至目前，普宁中 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥125,858,164.21, an improvement from -¥195,645,914.65 in the previous year[14]. - The net cash flow from operating activities was -¥190,179,871.80, compared to -¥316,747,838.83 in the same period last year[14]. - The total assets at the end of the reporting period were ¥14,587,349,688.80, down 3.47% from ¥15,111,759,138.19 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company decreased by 1.75% to ¥6,825,462,029.68 from ¥6,947,130,703.24 at the end of the previous year[14]. - The basic earnings per share for the first half of 2023 was -¥0.009, compared to -¥0.014 in the same period last year[15]. - The weighted average return on net assets was -1.83%, slightly improved from -1.99% in the previous year[15]. - The company reported a non-recurring profit of approximately ¥80.27 million for the period, primarily from non-operating income sources such as asset disposals and government subsidies[17]. - The company’s revenue for the first half of 2023 reached ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[49]. - Operating costs increased by 32.15% to ¥1,961,303,652.22 from ¥1,484,203,044.92, primarily due to the rise in revenue[49]. - Research and development expenses surged by 91.72% to ¥23,578,605.73, reflecting the company's increased investment in R&D projects[49]. - The company reported a net cash flow from operating activities of -¥190,179,871.80, an improvement from -¥316,747,838.83 in the previous year[49]. - Other income rose by 91.62% to ¥36,483,714.88, driven by an increase in government subsidies[51]. - Investment income skyrocketed by 285,176.16% to ¥21,872,550.99, attributed to the disposal of long-term equity investment assets[51]. Industry Position and Strategy - The pharmaceutical industry is increasingly integrated with the "big health" concept, with a focus on innovation and quality improvement, as highlighted by recent government policies[19]. - The company holds a leading position in the Chinese herbal medicine market, with a significant share of its revenue coming from traditional Chinese medicine (TCM) products, particularly herbal pieces[19]. - The company has established nine production bases across various provinces, capable of producing over 1,000 types and more than 20,000 specifications of herbal products[19]. - The company has over 550 patents and software copyrights, demonstrating its strong capability in technological innovation within the TCM sector[19]. - The company is recognized as a national technology innovation demonstration enterprise and a pilot demonstration enterprise for intelligent manufacturing in herbal pieces[19]. - The company’s business model encompasses the entire TCM supply chain, from cultivation and processing to sales and distribution through various channels[20]. - The company is positioned to benefit from the ongoing reforms and investments in the healthcare sector, which are expected to drive growth in the TCM industry[19]. - The company’s focus on integrating modern logistics and e-commerce into its distribution strategy aims to enhance market reach and operational efficiency[20]. - Key products include unique traditional Chinese medicines such as Baoning Banxia Granules and chemical drugs like Acetaminophen Powder, addressing significant market needs in cardiovascular, respiratory, and endocrine fields[21]. - The company has established deep business partnerships with over 1,100 medical institutions and more than 40,000 chain pharmacies nationwide, enhancing its market reach[27]. - The company has implemented a full industry chain integrated operation model, covering everything from raw material planting to sales through various channels including hospitals, OTC, and e-commerce[26]. Research and Development - The company has developed 497 small-scale trial varieties and 199 pilot varieties for traditional Chinese medicine (TCM) formula granules, with 135 varieties completed for market filing[28]. - The company holds over 550 intellectual property rights, including 6 newly authorized invention patents during the reporting period[29]. - The company has submitted technical materials for national processing standards for 9 TCM varieties and contributed to the drafting of national standards for TCM processing[30]. - The company has implemented a quality control model across the entire TCM industry chain, ensuring strict adherence to production standards and quality management[31]. - The company has maintained a record of "0 violations, 0 reports, 0 blacklists" in the industry, receiving positive feedback from hospitals, pharmacies, and consumers[32]. - The company is focusing on high-quality development in line with national strategies, optimizing its organizational structure and enhancing internal controls[34]. - The company is actively promoting innovation in TCM, including the development of formula granules and food-medicine integration products[34]. - The company has invested in advanced detection equipment and established a testing center exceeding 3,100 square meters to ensure product quality[31]. Environmental and Social Responsibility - The company has complied with environmental regulations and has not experienced any environmental pollution incidents during the reporting period[61]. - The company has implemented a self-monitoring plan for pollution discharge and regularly conducts technical testing services[68]. - The company’s environmental protection measures include a comprehensive emergency response plan for environmental incidents[67]. - The company is committed to green operations and has taken measures to prevent environmental pollution and risks[63]. - The company has established a standardized turtle breeding base in collaboration with a local cooperative, benefiting over 140 farmers with an approximate income increase of 20%[73]. - The company has assisted 1,079 registered households in Yunnan Province, helping 171 households and 30 disabled individuals find employment, with a total of approximately 8,360 job opportunities created[73]. - The company has invested over 150,000 yuan in medical resources for grassroots health services during the reporting period[75]. - The company has supported over 8,300 students from Jieyang to pursue higher education through its university student foundation by mid-2023[74]. - The company is committed to enhancing its corporate social responsibility by continuing to promote rural revitalization and poverty alleviation initiatives[76]. Governance and Compliance - The company has established a compliance management system to address increasing regulatory scrutiny in the pharmaceutical industry[57]. - The company commits to maintaining the independence of its business operations and governance structure, ensuring no interference from controlling entities[80]. - There are no significant non-operating fund occupations by controlling shareholders or related parties during the reporting period[81]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[84]. - The company has not provided any guarantees that are overdue or have not been fulfilled during the reporting period[87]. - The company has a complete and independent business process and decision-making capability for its subsidiaries[80]. - The company has a three-year shareholder return plan for 2023-2025 approved at the annual general meeting[59]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 200,443[91]. - The largest shareholder, Guangdong Shennongshi Enterprise Management Partnership, holds 3,509,413,788 shares, accounting for 25.31% of total shares[92]. - The second largest shareholder, Kangmei Industrial Investment Holdings, holds 723,176,677 shares, representing 5.21%[92]. - The total number of shares held by the top ten shareholders includes significant pledges, with the largest pledge being 715,509,782 shares by Kangmei Industrial Investment Holdings[92]. - The company has not reported any changes in share capital structure during the reporting period[90]. - There are no significant changes in the number of restricted shares that can be traded[94]. Financial Reporting and Accounting - The financial statements have been approved by the board of directors on August 17, 2023[123]. - The company has no significant factors affecting its ability to continue as a going concern within the next 12 months[126]. - The financial statements are prepared in accordance with the latest accounting standards issued by the Ministry of Finance, reflecting the company's financial position, operating results, and cash flows accurately[127]. - The accounting period for the financial report is from January 1, 2023, to June 30, 2023[128]. - The company uses RMB as its accounting currency[130]. - The company follows the accounting treatment methods for mergers under common control and non-common control, ensuring proper recognition of goodwill and investment income[130]. - The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, prepared in accordance with the relevant accounting standards[132]. - The company recognizes joint arrangements and applies appropriate accounting treatments for joint operations and joint ventures[134].

康美药业股份有限公司 第九届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届监事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位监事发出，会议应参加表决监事 3 名，实际参 加表决监事 3 名。本次会议由监事会主席高燕珠女士主持，会议的召集、召开程 序符合《公司法》《证券法》及《公司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 证券代码：600518 证券简称：ST康美 编号：临2023-029 康美药业股份有限公司监事会 二〇二三年八月十九日 1 ...

证券代码：600518 证券简称：ST康美 编号：临2023-028 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 康美药业股份有限公司董事会 二〇二三年八月十九日 1 康美药业股份有限公司 第九届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届董事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位董事发出，会议应参加表决董事 9 名，实际参 加表决董事 9 名。本次会议由董事长赖志坚先生主持，公司全体监事和部分高级 管理人员列席了会议，会议的召集、召开程序符合《公司法》《证券法》及《公 司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 9 票，反对票 0 票，弃权票 0 票。 ...

证券代码：600518 证券简称：ST康美 编号：临2023-027 康美药业股份有限公司 关于公司涉及重大诉讼的结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：公司 2022 年度已根据会计准则相 关规定，基于审慎性原则，依据一审判决结果，以康美中药城、新世界商贸、世 纪国药被抵押的不动产账面价值为限计提未决诉讼预计负债共计 60,916.28 万 元，减少公司 2022 年度归属于上市公司股东的净利润 60,916.28 万元。本判决 对公司 2023 年度利润具体影响以案件最终执行情况为准。公司将继续保留法律 权利，依据相关规定，维护公司及股东的合法权益，及时履行信息披露义务。 康美药业股份有限公司（以下简称公司）于今日收到广东省高级人民法院 （2022）粤民终 4309 号《民事判决书》，就渤海国际信托股份有限公司与康美 （亳州）华佗国际中药城有限公司、亳州市新世界商贸有限公司等金融借款合同 纠纷诉讼，作出二审终审判决，具体如下： 一、诉讼的基本情况 3、原告 ...

证券代码：600518 证券简称：ST康美 编号：临2023-026 康美药业股份有限公司关于康美实业 所持公司部分股份将被司法拍卖的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次将被司法拍卖的股份为康美实业投资控股有限公司（以下简称康美 实业）持有的公司无限售流通股 155,290,000 股，占公司总股本的 1.12%。 截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股本 的 5.21%。若本次司法拍卖成功，不会导致公司控股股东及实际控制人发生变化， 亦不会对公司经营活动产生影响。 目前上述司法拍卖事项尚在公示阶段，后续将涉及竞拍、缴款、股权变 更过户等环节，拍卖结果尚存在不确定性，公司将根据后续进展及时履行信息披 露义务。 康美药业股份有限公司（以下简称公司）今日获知，康美实业管理人将依法 分批公开处置康美实业持有的公司股票，第一批司法拍卖股票标的为康美实业持 有的公司无限售流通股 155,290,000 股，占公司总股本的比例为 1.12%，现将本 次拍卖的情 ...